{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Fotivda"},{"type":"ForeignBrandName","name":"Fotivda"},{"type":"Synonym","name":"tivozanib hydrochloride hydrate"},{"type":"Synonym","name":"tivozanib monohydrochloride monohydrate"},{"type":"CASRegistryName","name":"682745-41-1"}],"definition":{"html":"The hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","text":"The hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/tivozanibhydrochloride","text":"Tivozanib Hydrochloride"},"nciConceptId":"C152666","nciConceptName":"Tivozanib Hydrochloride","termId":561728,"name":"tivozanib hydrochloride","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tivozanib-hydrochloride"}],"links":null}